Page last updated: 2024-11-13

n-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1h-indazole-3-carboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide: a synthetic cannabinoid known as black mamba [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID86280478
SCHEMBL ID16201697
MeSH IDM0591057

Synonyms (14)

Synonym
1633766-73-0
unii-u1q4f41c9u
n-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1h-indazole-3-carboxamide
dea no. 7035
u1q4f41c9u ,
adb-pinaca
1h-indazole-3-carboxamide, n-(1-(aminocarbonyl)-2,2-dimethylpropyl)-1-pentyl-
SCHEMBL16201697
n-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-pentyl-1h-indazole-3-carboxamide
Q18209025
DTXSID301010007
1h-indazole-3-carboxamide, n-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-pentyl-
CA175142
adb-pinaca-d9
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies2 (33.33%)4.05%
Observational0 (0.00%)0.25%
Other3 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]